XTL Biopharmaceuticals Ltd
Save
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.

Similar securities

Based on sector and market capitalization

Report issue